Description

According to a report by StrategyHelix, the global biopharmaceutical contract manufacturing market is set to increase by US$ 9.0 billion during 2022-2028, growing at a CAGR of 8.9% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for biopharmaceutical contract manufacturing. The global biopharmaceutical contract manufacturing market is segmented on the basis of product, service, source, organization size, and region. On the basis of product, the global biopharmaceutical contract manufacturing market has been segmented into biologics, biosimilars. The biologics segment held the largest revenue share in 2021. By service, the global biopharmaceutical contract manufacturing market has been segmented into analytical and QC studies, fill and finish operations, packaging, process development. Based on source, the global biopharmaceutical contract manufacturing market is categorized into mammalian, microbial-based biologics/non-mammalian. The mammalian segment captured the largest share of the market in 2021. On the basis of organization size, the global biopharmaceutical contract manufacturing market has been segmented into large enterprises, small and medium-sized enterprises (SMEs). According to the research, the large enterprises segment had the largest share in the global biopharmaceutical contract manufacturing market. Geographically, the global biopharmaceutical contract manufacturing market is segmented into North America, Europe, Asia-Pacific, Rest of the World.

The biologics market is further segmented into monoclonal antibodies (mAbs), recombinant proteins, vaccines, and others. Globally, the mAbs segment made up the largest share of the biopharmaceutical contract manufacturing market.

The global biopharmaceutical contract manufacturing market is highly competitive. The prominent players operating in the global biopharmaceutical contract manufacturing market include AbbVie Inc., Ajinomoto Co. Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Catalent Inc., Emergent BioSolutions Inc., FUJIFILM Holdings Corporation, Lonza Group AG, Merck KGaA, Pfizer Inc., Samsung Biologics Co. Ltd., Serum Institute Of India Pvt. Ltd., Thermo Fisher Scientific Inc., WuXi Biologics Inc.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the biopharmaceutical contract manufacturing market to help drive informed decision making for industry executives, policy makers, academic, and analysts.


Report Scope

Product: biologics, biosimilars
Service: analytical and QC studies, fill and finish operations, packaging, process development
Source: mammalian, microbial-based biologics/non-mammalian
Organization size: large enterprises, small and medium-sized enterprises (SMEs)
Region: North America, Europe, Asia-Pacific, Rest of the World
Years considered: this report covers the period 2018 to 2028


Key Benefits for Stakeholders

– Get a comprehensive picture of the global biopharmaceutical contract manufacturing market
– Pinpoint growth sectors and trends for investment


Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Biopharmaceutical contract manufacturing market overview
Part 3. Market breakdown by product
– Biologics
– Biosimilars
Part 4. Market breakdown by service
– Analytical and QC studies
– Fill and finish operations
– Packaging
– Process development
Part 5. Market breakdown by source
– Mammalian
– Microbial-based biologics/non-mammalian
Part 6. Market breakdown by organization size
– Large enterprises
– Small and medium-sized enterprises (SMEs)
Part 7. Market breakdown by region
– North America
– Europe
– Asia-Pacific
– Rest of the World
Part 8. Key companies
– AbbVie, Inc.
– Ajinomoto Co. Inc.
– Boehringer Ingelheim Biopharmaceuticals GmbH
– Catalent, Inc.
– Emergent BioSolutions Inc.
– FUJIFILM Holdings Corporation
– Lonza Group AG
– Merck KGaA
– Pfizer Inc.
– Samsung Biologics Co., Ltd.
– Serum Institute Of India Pvt. Ltd.
– Thermo Fisher Scientific, Inc.
– WuXi Biologics, Inc.
About StrategyHelix
Disclaimer


USD 650

Product Type

Industry Statistics

Release Date

July 2022

Region

Global

Pages

15

REQUEST SAMPLE

Global Biopharmaceutical Contract Manufacturing Market 2022

Please fill out our form and we will get back to you.

CUSTOM RESEARCH

Global Biopharmaceutical Contract Manufacturing Market 2022

Please fill out our form and we will get back to you.

login